Jim Cramer's Stop Trading: GILD KORS

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, looked at shares of Gilead Sciences (GILD). 

Wells Fargo said Gilead's Hepatitis C drug, Solvadi, will do better than expected. That research note gave  shares a slight boost on Tuesday and could help reverse the stock, which has declined precipitously since March, Cramer said. 

Getting long Gilead Sciences is not "a fool's errand" and growth stocks may be beginning to stabilize at current levels, he added.

Turning to Michael Kors (KORS), he was "a little nervous" about a rally higher from current levels. 

While he admitted to liking Michael Kors, Cramer said there is a "tug of war" between bulls and bears, making it difficult to interpret which way the stock will go. 

He said the company's lack of disclosure and clarity is not helping the situation, as pointed out by TheStreet's Herb Greenberg.

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside